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Aims: To compare long-term changes in healthcare utilization and costs for type 2 diabetes
patients before and after insulin initiation, as well as healthcare costs after insulin versus
non-insulin anti-diabetic (NIAD) initiation.
Methods: Patients newly initiated on insulin (n = 2823) were identified in primary health care
records from 84 Swedish primary care centers, between 1999 to 2009. First, healthcare costs
per  patient were evaluated for primary care, hospitalizations and secondary outpatient care,
before and up to seven years after insulin initiation. Second, patients prescribed insulin in
second line were matched to patients prescribed NIAD in second line, and the healthcare
costs  of the matched groups were compared.
Results: The total mean annual healthcare cost increased from D 1656 per patient 2 years
before insulin initiation to D 3814 seven years after insulin initiation. The total cumulative
mean healthcare cost per patient at year 5 after second-line treatment was D 13,823 in the
insulin group compared to D 9989 in the NIAD group.
Conclusions: Initiation of insulin in type 2 diabetes patients was followed by increasedhealthcare costs. The increases in costs were larger than those seen in a matched patient
population initiated on NIAD treatment in second-line.
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1.  Introduction
The prevalence of drug treated type 2 diabetes mellitus (T2DM)
in Sweden is increasing and has recently been reported
to be 4.4% [1]. T2DM is a major cause of morbidity and
premature mortality, primarily through macrovascular and
microvascular complications [1–5]. The disease and its compli-
cations increase the use of healthcare services with associated
increases in total healthcare costs [6–8].
Glycemic control is a cornerstone in T2DM management
to avoid diabetes related complications, where insulin is con-
sidered to be an effective HbA1c lowering intervention [9]. In
Sweden, with a relatively high use of insulin compared to
other European countries, insulin has now surpassed sulpho-
nylurea as the most commonly dispensed drug in second-line
add-on to metformin [10,11]. This “treatment ladder” is in line
with the Swedish national guidelines, recommending second
line insulin when metformin fails, only subsequently followed
by other available glucose lowering drugs [12]. International
T2DM guidelines however recommend several options as sec-
ond line treatment, including also more  innovative second
line treatment options, such as dipeptidyl peptidase (DPP)-
4 inhibitors, sodium glucose cotransporter 2 inhibitors and
glucagon-like peptide-1 receptor agonists (GLP-1RA) [13,14].
In addition to the benefits on glucose levels, insulin also
carries a number of unwanted side effects like weight gain,
hypoglycemia, reactions from injections and increased treat-
ment complexity [15–18]. Furthermore, recent studies report
associations between insulin and increased risk of cancer,
cardiovascular disease and all-cause mortality [18–20]. Thus,
despite the low direct cost of insulin treatment, unwanted
side effects and treatment complexity of insulin may lead
to increased long-term health care costs [21–23]. Despite sev-
eral studies on health care costs and T2DM [24–30] there are
limited data on use of health care resource associated with
insulin. Since insulin is widely used in Sweden, a cost analy-
sis might contribute useful evidence to the understanding of
the implications for the healthcare system of the insulin use.
Recently, one study has reported increased health care costs
after insulin initiation, but findings were limited to a highly
selected group of patients with no hospitalization data, low
representativity and short follow-up [31].
The aim of this study was to compare long-term changes in
healthcare utilization and costs before and after insulin initi-
ation in Sweden. In addition, also to compare healthcare costs
after insulin versus non-insulin anti-diabetic (NIAD) initiation.
2.  Material  and  methods
2.1.  Study  sample
Patients diagnosed with type 2 diabetes mellitus (ICD E11)
and/or prescription of any blood glucose-lowering drug
(ATC A10) were identified at 84 primary-care centers inPlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
Sweden between 1 January 1999 to 31 December 2009
(www.clinicaltrials.gov; NCT: 01121315). Effort was made to
ensure a representative selection of primary care centers [8].
A total of 58 333 patients could be included, and data linked tox x x ( 2 0 1 6 ) xxx–xxx
the Swedish National Patient-, Prescribed Drug- and Cause of
Death registries by using the unique personal identification
number, mandatory for all citizens from birth or immigra-
tion. Details on study design and the data extraction from
primary care records and registers have been described else-
where [2,4,8,22,32].
2.2.  The  insulin  initiation  cohort
This cohort is used to compare long-term changes in health-
care utilization and costs before and after insulin initiation in
all patients. The cohort will also be important when assess-
ing the representativity of the smaller matched second line
cohort, see below. We identified all patients >30 years of age
initiating insulin after having 15 months with no insulin pre-
scription to be included. Patients were excluded if they had
no registered visit or contact in the electronic patient record
within two years prior to index treatment start. Any gap larger
than 15 months between prescriptions was considered as
discontinuation. In order to control for other cost driving co-
morbidities, we excluded all patients with history of CVD  and
cancer at baseline. Patients with any hospital visit (in hos-
pital stay or outpatient clinic visit) within 90 days prior to
insulin initiation were excluded. Patients were followed from
two years prior to index date and until discontinuation, death
or end of study period from electronic patient records.
2.3.  Matched  second  line  cohort
In order to compare healthcare costs after insulin initiation
with healthcare costs after initiation of NIADs, we  defined
two similar groups. We  identified patients with metformin
monotherapy for at least 2 years and no gaps of more  than
15 months between two prescriptions. They were indexed
when they either were prescribed second line insulin (Insulin
group) or second line non-insulin antidiabetic drug (NIAD
group). To reduce the likelihood of rescue insulin treatment,
only patients with two prescriptions within 15 months were
included. Any gap larger than 15 months between second line
prescriptions was considered as discontinuation.
2.4.  Patient  baseline  characteristics
Baseline data were extracted from electronic patient records
for the variables of systolic and diastolic blood pressure; total-
, low density lipoprotein (LDL) and high density lipoprotein
(HDL) cholesterol; serum triglycerides; HbA1c values; lipid-
lowering-, glucose-lowering- and blood pressure-lowering
drugs; and estimated glomerular filtration rate (eGFR), age and
sex. Data on HbA1c is reported in DCCT.
Disease history at baseline was collected by searching for
diagnoses coded with International Classification of Diseases,
9th (ICD-9) and 10th (ICD-10) revision in primary care- and
hospital data, defined in an earlier publication [8].
2.5.  Healthcare  resource  use utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
All patient healthcare resource use (primary care, inpatient
care (hospitalizations) and/or secondary outpatient care),
both diabetes and non-diabetes related, was considered and
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Table 1 – Unit costs applied in the analyses.
Cost item Unit cost (D )
Primary care Per contact
GP visit 148
GP home visit 296
GP phone
contact/administration work
49
Nurse visit 54
Nurse home visit 108
Nurse phone contact/patient
administration
18
Other primary care visit 54
Other primary care home visit 108
Other primary care phone
contact/patient administration
18
Laboratory visit 57
Hospitalizations Per event
Cardiovascular 5336
Gastrointestinal 4853
Urogenital 5067
Cancer 7081
Respiratory 5181
Endocrine 4990
Musculoskeletal 6552
Neurological 5833
Infections 5729
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lowed up to 7 years (mean 3.8 years and total number of patientAll other causes 3370
D 1 = 8.7034 SEK (2012 values).
ncluded. Data on primary care use was extracted from elec-
ronic patient records and consisted of visits to physician,
urse, and other primary care professions such as physio-
herapist, podiatrist, laboratory tests and administration (e.g.,
rescription renewal).
Primary care contacts were obtained by item through
he primary care medical records. Hospitalizations and sec-
ndary outpatient care were extracted from the mandatory,
wedish National Patient Register. Hospitalizations were clus-
ered into 10 diagnosis-related groups based on the main ICD-9
nd ICD-10 codes assigned to a hospitalization (cardiovascu-
ar, gastrointestinal, urogenital, cancer, respiratory, endocrine,
usculoskeletal, neurological, infectious and all others). For
econdary outpatient visits the 25 most frequent diagnoses
ased on the ICD-9 and ICD-10 were identified.
.6.  Cost  assignment
nnual healthcare costs per patient were evaluated from
he healthcare perspective for the resource use in primary
are, hospitalizations and secondary outpatient care. In order
o estimate costs before and after the initiation of insulin,
wedish unit costs were applied to the healthcare resource
se data (Table 1). Unit costs for primary care visits were
xtracted from cost databases with nationwide average costs
er contact. Unit costs for hospitalizations, with the excep-
ion of cancer and other causes, were extracted from the cost
er patient database from the Swedish Association of Local
uthorities and Regions (KPP database). Since no uniformPlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
CD code is available for cancer, unit costs for cancer-related
ospitalizations were estimated by applying the mean cost per
ospitalization based on diagnosis-related group (DRG) cost x x ( 2 0 1 6 ) xxx–xxx 3
weights. Unit costs for hospitalizations that falls into the ICD
group of other causes were calculated by deriving the weighted
average costs of the fifteen most commonly observed diag-
noses in the sample. For secondary outpatient care, unit costs
for the 25 most frequent ICD-9 and ICD-10 codes were assessed
using the KPP database (Appendix A). For the remaining causes
in secondary outpatient care, the average cost for all diag-
noses was used. All unit costs are in year 2012 values (average
exchange rate: D 1 = SEK 8.7034). Since Sweden has had a neg-
ligible deflation in the general price level since year 2012, the
values from 2012 are assumed to still be relevant (Consumer
price index, CPI: 2015 = 1, 2012 = 0.997). Costs of pharmaceuti-
cals and devices of glucose monitoring are excluded from this
study because prescription data were not available for the full
study period. More details on the cost assessment have been
described previously [22].
2.7.  Statistical  analysis
Descriptive statistics on an aggregated level were used to dis-
play baseline patient characteristics, resource utilization, and
annual costs per patient in the dataset. For continuous vari-
ables, the mean is presented. For categorical variables, the
number and proportions (percentage) in each category are pre-
sented. The per patient mean consumption of primary care,
hospitalizations and secondary outpatient care is reported for
the full study period and by yearly intervals in order to explore
patterns in resource use over time. Annual costs per patient
were estimated by applying the unit costs above, and pre-
sented in total as well as by healthcare category (primary care,
hospitalization and secondary outpatient care).
The insulin and NIAD group patients were matched 1:1 on
mean two-year cost before index, HbA1c, age and gender.
For many  patients the follow-up was shorter than the max-
imum observation time of 7 years due to death or censoring
at the end of the study period. To account for censoring, the
partitioned method of Bang and Tsiatis was used for calcu-
lating the mean annual costs for contacts in primary care,
hospitalisations and secondary outpatient care [33].
2.8.  Ethical  approval
The study was approved by the Regional Ethical Review Board
in Uppsala, Sweden (Dnr. 2010/077).
3.  Results
Of 58,333 T2DM patients; 2823 patients fulfilled the criteria and
could thus be included. Patients were most frequently initi-
ated on medium long acting (NPH) followed by mixed medium
long-, long acting and short acting insulin. Patients were fol- utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
years 10,727). Mean age of patients at initiation of insulin was
61 years and 42% were female. Mean patient HbA1c level was
8.7%. Further baseline characteristics are reported in Table 2.
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Table 2 – Baseline characteristics.
All patients started with insulin Before matching Matched patients (1:1)
Insulin NIAD Insulin NIAD
Number of patients, N 2823 511 1859 432 432
Age, years, 60.8 (11.1) 59.4 (11.0) 59.3 (11.5) 59.5 (10.1) 59.5 (10.1)
Sex, male, n (%) 1645 (58.3) 279 (54.6) 1028 (55.3) 243 (56.2) 253 (58.6)
Follow up, years 3.8 (2.6) 4.2  (3.1) 3.3 (2.6) 4.0 (3.0) 3.2 (2.6)
Time on metformin monotherapy (days) n/a 787.7 (752.2) 831.4 (727.6) 795.1 (760.0) 797.9 (696.0)
Insulin type, n (%)
Short acting 90 (3.2) 15 (3.0) 14 (3.3)
Medium acting 1558 (55.2) 282 (57.1) 243 (57.9)
Mixed medium/long acting 620 (22.0) 92 (18.6) 71 (16.9)
Long acting 554 (19.6) 105 (21.3) 92 (21.9)
Cardiovascular disease, n (%) 0 0 (0) 0 (0) 0 (0) 0 (0)
Myocardial infarction 0 0 (0) 0 (0) 0 (0) 0 (0)
Stroke 0 0 (0) 0 (0) 0 (0) 0 (0)
Heart failure 0 0 (0) 0 (0) 0 (0) 0 (0)
Atrial fibrillation 0 0 (0) 0 (0) 0 (0) 0 (0)
Other disease, n (%) 0 0 (0) 0 (0) 0 (0) 0 (0)
Cancer 0 0 (0) 0 (0) 0 (0) 0 (0)
Kidney disease 0 0 (0) 0 (0) 0 (0) 0 (0)
Laboratory measurements
HbA1c, % 8.7 (2.8) 8.8 (2.9) 8.2 (2.6) 8.6 (2.6) 8.6 (2.6)
Glucose, mmol/l 10.5 (3.7) 11.1 (4.1) 9.8 (3.0) 10.9 (3.9) 11.1 (3.2)
BMI, kg/m2 29.9 (5.5) 31.5 (5.2) 31.9 (5.7) 31.4 (5.0) 32.1 (5.7)
Systolic blood pressure, mmHg 142.9 (18.7) 141.5 (17.5) 142.3 (17.6) 141.6 (17.3) 143.3 (17.3)
Diastolic blood pressure, mmHg 80.6 (9.8) 81.6 (9.2) 81.9 (9.8) 81.5 (9.1) 82.5 (9.8)
Total cholesterol, mmol/l 5.1 (1.1) 5.0 (1.2) 5.2 (1.1) 5.0 (1.2) 5.3 (1.2)
HDL cholesterol, mmol/l 1.3 (0.7) 1.4 (0.8) 1.3 (0.7) 1.4 (0.8) 1.2 (0.5)
LDL cholesterol, mmol/l 2.9 (0.9) 2.9  (0.9) 3.0 (0.9) 2.9 (0.9) 3.1 (0.9)
Triglycerides, mmol/l 2.2 (1.8) 2.2 (1.8) 2.4 (1.6) 2.2 (1.8) 2.4 (1.8)
Creatinine, mol/l 78.6 (21.6) 74.7 (20.0) 76.3 (19.9) 74.7 (19.4) 76.0 (17.8)
Estimated GFR, ml/min 84.0 (20.3) 87.9 (18.1) 86.8 (19.4) 88.1 (17.9) 87.1 (18.8)
Insulin/add-on treatment initiated, n (%)
1999 178 (6.3) 21 (4.1) 70 (3.8) 17 (3.9) 21 (4.9)
2000 206 (7.3) 27 (5.3) 100 (5.4) 17 (3.9) 29 (6.7)
2001 206 (7.3) 32 (6.3) 99 (5.3) 24 (5.6) 25 (5.8)
2002 201 (7.1) 36 (7.0) 120 (6.5) 28 (6.5) 26 (6.0)
2003 207 (7.3) 36 (7.0) 171 (9.2) 33 (7.6) 32 (7.4)
2004 237 (8.4) 36 (7.0) 153 (8.2) 34 (7.9) 27 (6.2)
2005 264 (9.4) 40 (7.8) 186 (10.0) 37 (8.6) 46 (10.6)
2006 263 (9.3) 46 (9.0) 204 (11.0) 36 (8.3) 42 (9.7)
2007 323 (11.4) 74 (14.5) 213 (11.5) 58 (13.4) 59 (13.7)
2008 253 (12.5) 76 (14.9) 272 (14.6) 65 (15.0) 59 (13.7)
erwis2009 385 (13.6) 
All numbers in parenthesis are standard deviation if not stated oth
glomerular filtration rate.
3.1.  Healthcare  costs  of  patients  initiated  on  insulin
The total mean annual healthcare costs increased from D 1655
per patient 2 years before insulin initiation to D 3814 seven
years after insulin initiation (Fig. 1). Almost half of the total
increase in mean annual healthcare cost occurred already
in year 1, after which the costs continued increasing gradu-
ally. Throughout the study period, primary care represents the
largest portion of the total healthcare costs (43–59%), closely
followed by hospitalisation (31–40%). Primary care costs arePlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
especially elevated one year after insulin initiation, while hos-
pitalisation costs increase steadily over time. The costs for
secondary care outpatient visits keep a relatively small share
(10–16%) of total costs throughout the study period. Mean per87 (17.0) 272 (14.6) 83 (19.2) 66 (15.3)
e. HDL, high density lipoprotein, LDL, low density lipoprotein, GFR,
patient cumulative healthcare costs were D 14,211 at 5 years
and D 21,334 at 7 years of observation. Primary care had a
higher cumulative cost compared with hospital care, D 10,001
and D 8188 at year 7, respectively.
3.2.  Healthcare  costs  after  second  line  insulin  versus
NIAD
Overall, 511 patients fulfilled the inclusion criteria of having
metformin monotherapy for at least 2 years with no gaps of utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
more  than 15 months between two prescriptions, and being
initiated on second line insulin or NIAD. The unmatched
patients who initiated insulin compared to NIAD had slightly
higher levels of HbA1c and blood glucose but were similar in
ARTICLE IN PRESSPCD-568; No. of Pages 9
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ll other respects. The matched groups shared similar charac-
eristics compared to the larger group of all patients initiating
nsulin, hence the representativity seems to be appropriate.
The total cumulative mean healthcare cost per patient at
ear 5 after second-line treatment with insulin was D 13,823,
ith hospitalizations as the main cost driver representing
2–51% of total cumulative costs, followed by primary care
isits (33–46% of total cost) and outpatient visits (12–16% of
otal cost). The total cumulative mean healthcare cost per
atient at year 5 after second-line treatment with NIAD was
 9989, with the same distribution in cost categories as for the
nsulin group (Fig. 2). Healthcare costs after second line insulin
nitiation exhibit a 12-fold increase compared to two years
efore insulin initiation, while the healthcare costs after sec-
nd line with NIAD exhibit an 8-fold increase. The difference
n cumulative healthcare costs between second line insulin
nd second line NIAD appeared already in year 1 and contin-
ed to increase during follow-up (Fig. 3). Hence the increase
n healthcare costs associated with insulin initiation is
onsiderably higher that the increase seen after NIAD initi-
tion in second-line.
.  DiscussionPlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
ased on data from a large Swedish observational study of
2DM patients, this study demonstrates two important find-
ngs; the increased healthcare use and costs after insulin
nitiation; and significantly higher cumulative costs amongars prior to insulin start and the years thereafter.
patients initiated on second line insulin compared to patients
initiated on second line non-insulin anti-diabetics (NIADs).
The insulin initiation resulted in a sharp rise of total
healthcare costs within the first year, and was followed by con-
tinuously increased total healthcare costs up to 7 years. Mean
annual healthcare costs per patient increased 230% over the
7 years. A recent Swedish study has also reported increased
healthcare costs 1 year after insulin initiation, although at
somewhat different rates than those reported here [31]. In
the study by Bexelius et al., the costs increased from D 1980
the year before insulin initiation to D 3637 already the year
after (2012 values, 1D = 8.7034 SEK). One possible explana-
tion for this discrepancy is that in contrast to Bexelius et al.,
using data from 100 patients in 1 Swedish county coun-
cil, this study included geographically dispersed (rural and
urban) primary care centers as well as the nationwide Swedish
National Patient-, Prescribed Drug- and Cause of Death reg-
istries. Another possible explanation for the difference is
the stricter inclusion criteria in the present study, excluding
patients with known CVD or cancer, or patients who  were hos-
pitalized within 90 days prior to insulin initiation, to control
for expensive co-morbidities in order to get more  accurate
estimates of the changes in costs directly linked to insulin
initiation.
Baseline characteristics of the unmatched insulin group
show that these patients have higher HbA1c and receive utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
slightly earlier add-on treatment than do NIAD patients. This
could imply a more  progressed disease or later diagnosis set-
ting in the insulin group. A previous study has demonstrated
the relationship between costs and HbA1c level, where a 1%-
ARTICLE IN PRESSPCD-568; No. of Pages 9
6  p r i m a r y c a r e d i a b e t e s x x x ( 2 0 1 6 ) xxx–xxx
Fig. 2 – Cumulative mean cost per patient prior and after add-on treatment in patients treated with insulin (upper pane) and
patients treated with NIAD (lower pane).
point increase in HbA1c led, on average, to a 4.4% increase in
diabetes-related medical costs for type 2 diabetes [34]. This
relationship could help explain the cost increase over time
as the disease progresses. In the present study, on matching
the insulin patients in HbA1c and other important variables to
patients receiving NIAD-treatment in second line, the insulinPlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
initiation was followed by a higher use of healthcare ser-
vices and a larger increase in total healthcare costs, than
non-insulin treatment. To our knowledge, the present studyis the first to compare healthcare costs of patients initiated
on second line insulin to a matched group of patients initiat-
ing second line with another NIAD. The difference in health
care costs was visible already after the first year and contin-
ued to grow during 5 year observation period. At year 5, insulin
patients had incurred D 3800 more  in cumulative healthcare utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
costs per patient than non-insulin patients. The difference
in costs is striking, especially in the view that insulin is put
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Fig. 3 – Increase in cumulative mean cost per patient year
1–5 versus date of add-on treatment in patients treated
with insulin (red full line) and patients treated with NIAD
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color in this figure legend, the reader is referred to the web
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Appendix  A.ersion of this article.)
orward for its alleged low cost compared to non-insulin treat-
ents [13].
The increase in primary care contacts is of particular
nterest as it indicates a need for a more  intense follow up
fter insulin initiation. In Sweden, interaction with diabetes
eams after insulin initiation is well established and recom-
ended in the national guidelines, which could help explain
he increase in primary care costs. In addition, hospitaliza-
ions increased substantially in the first year after insulin
nitiation, compared to patients prescribed non-insulin treat-
ent. The observed difference in hospitalization costs may be
ainly related to the adverse effects of insulin, particularly
ypoglycemia, that require additional healthcare. Despite the
nown benefits with early insulin initiation [35–37], it also
arries a number of unwanted side effects [11,15–17]. Hypo-
lycemic responses, such as sympathoadrenergic activation,
re suspected to act as a causal pathway between insulin treat-
ent and risk of CVD, mortality, and potential serious cardiac
rrhythmias [38].
Furthermore, the increased hospitalization might be linked
o weight gain, which is a well-known side-effect of insulin
reatment. Several studies have shown that overweight is a
ajor contributor to the increased risk for CV morbidity and
ortality in T2DM patients [8,32,39,40]. In addition, treat-
ent induced weight gain has been reported as having a
egative effect on adherence to diabetic medications [41]. Con-
equently, several studies have shown that weight changes in
2DM-patients had effect on healthcare costs due to increasedPlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
ealthcare consumption [42–44]. For instance, every unit gain
n BMI  was found to be associated with 20% increase in costs
mong patients who increased their BMI over 12 months
change in BMI  >0) [44]. x x ( 2 0 1 6 ) xxx–xxx 7
Previous research of healthcare costs for T2DM in Sweden
has evaluated costs for 1 year at a time, and often in lim-
ited cohorts [24–31]. This study longitudinally follows patients’
healthcare use and cost development after initiation of insulin
in a large patient cohort (n = 2823). Patients with data 2 years
prior to insulin initiation were deliberatively chosen to depict
the changes in costs after insulin initiation. By using a large
data material from 84 primary care centers from different
parts of Sweden, selection bias has been reduced. However,
this study also has limitations. One is the relatively small
number of patients available for the full 7 year observa-
tion period. The representativeness of the cohorts included
could be questioned, supporting the importance to compare
the larger insulin initiating cohort to the second-line cohort
match. The matched cohort was very similar to all patients
who were initiated on insulin, and the 5-year cumulative mean
healthcare costs were similar in both insulin groups (D 13,823
versus D 14,211), supporting high internal representativeness.
The exclusion of patients who have previous experience of
CVD or cancer, or who were hospitalized within 90 days prior
to insulin initiation, was also performed to minimize the risk
for confounding. Another potential drawback are the included
cost items. Healthcare utilization is limited to primary care
visits, hospitalizations and secondary outpatient visits, and
does not account for other emergency care or outpatient care.
However, the main treatment of T2DM in Sweden is provided
by the included items, why this study gives a well-covered
estimate of the costs that follow insulin initiation.
5.  Conclusions
Initiation of insulin in type 2 diabetes patients were fol-
lowed by increased costs in primary, secondary outpatient and
hospital care, larger than those seen in a matched patient pop-
ulation initiated on non-insulin treatment in second-line. To
fully analyze the implications of insulin and NIAD treatment,
a cost-effectiveness analysis is required.
Conflict  of  Interest
AK, JB, and ME hold full-time positions at AstraZeneca. JS, BS,
CJÖ, PN and GJ have received compensation for their work
from AstraZeneca.
Acknowledgement
This study was sponsored by AstraZeneca. utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
Item costs used to calculate mean and median costs per indi-
vidual for outpatient visits. Cost reference: KPP Database.
ARTICLE IN PRESSPCD-568; No. of Pages 9
 t e s 
r
abetes8  p r i m a r y c a r e d i a b e
ICD10 EUR/admission Year Comments
297.58 2013
E11 190.16 2013
E10 290.81 2013
H25 167.52 2013
Z49 447.76 2013
Z09 237.84 2013
E14 295.40 2013
Z13 134.77 2013
H40 118.23 2013
I20 381.46 2013
C61 383.76 2013
I48 406.51 2013
Z01 183.38 2013
M17  290.23 2013
I25 312.06 2013
H35 305.97 2013
R10 341.71 2013
Z51 416.85 2013
Z08 478.89 2013
L40 277.71 2013
I70 316.77 2013
R07 392.95 2013
M79  410.30 2013
Z96 250.36 2013
M05  298.16 2013
other ICD codes 310.91 2013 mean for all
diagnosis
 e  f  e  r  e  n  c  e  s
[1] A. Norhammar, J. Bodegard, T. Nystrom, et al., Incidence,
prevalence, and mortality of type 2 diabetes requiring
glucose-lowering treatment, and associated risks of
cardiovascular complications: a nationwide study in
Sweden, 2006–2013, Diabetologia 5 (2016) (Epub ahead of
print).
[2] J. Sundstrom, R. Sheikhi, C.J. Ostgren, et al., Blood pressure
levels and risk of cardiovascular events and mortality in
type-2 diabetes: cohort study of 34 009 primary care
patients, J. Hypertens. 31 (8) (2013) 1603–1610.
[3] ADVANCE Collaborative Group, A. Patel, S. MacMahon, J.
Chalmers, et al., Intensive blood glucose control and
vascular outcomes in patients with type 2 diabetes, N. Engl.
J.  Med. 358 (24) (2008) 2560–2572.
[4] C.J. Östgren, J. Sundström, B. Svennblad, et al., Associations
of  HbA1c and educational level with risk of cardiovascular
events in 32,871 drug-treated patients with type 2 diabetes:
a  cohort study in primary care, Diabet. Med. 30 (5) (2013)
e170–7.
[5] R. Williams, L. Van Gaal, C. Lucioni, C.-A. Board, Assessing
the impact of complications on the costs of type II diabetes,
Diabetologia 45 (7) (2002) S13–7.
[6] P.E. Wandell, Quality of life of patients with diabetes
mellitus: an overview of research in primary health care inPlease cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
the Nordic countries, Scand. J. Prim. Health Care 23 (2) (2005)
68–74.
[7] P. Kanavos, S. van den Aardweg, W.  Schurer, Diabetes
Expenditure, Burden of Disease and Management in 5 EUx x x ( 2 0 1 6 ) xxx–xxx
Countries, The London School of Economics and Political
Science (LSE), London, UK, 2012.
[8] J. Bodegard, J. Sundstrom, B. Svennblad, et al., Changes in
body mass index following newly diagnosed type 2 diabetes
and  risk of cardiovascular mortality: a cohort study of 8486
primary-care patients, Diabetes Metab. 39 (4) (2013) 306–313.
[9] UK Prospective Diabetes Study (UKPDS) Group, Intensive
blood-glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33),
Lancet 352 (9131) (1998) 837–853.
[10] J. Bodegård, D. Nathanson, T. Nyström, et al., Second-line
treatment with sulphonylurea compared to DPP4 inhibitors
demonstrated associations with earlier treatment
intensification with insulin, in: Poster at the European
Association for the Study of Diabetes (EASD) Annual
Meeting, Stockholm, Sweden, 2015, Available from:
http://www.easdvirtualmeeting.org/resources/second-line-
treatment-with-sulfonylurea-compared-to-dpp4-inhibitors-
demonstrated-associations-with-earlier-treatment-
intensification-with-insulin-3.
[11] E. Heintjes, J. Overbeek, P. Blin, et al., Type 2 diabetes
treatment patterns across Europe [Poster], Value Health 17
(2014) A323–A686, Available from:
http://www.harmo.nl/uloads/df/Posters/T2DM%20treatment%
20atterns%20across%20Euroe ISPOR2014 20141030.pdf.
[12]  Socialstyrelsen, Nationella riktlinjer för diabetesvård. Stöd
för  styrning och ledning, National Guidelines for diabetes
care in Sweden, Socialstyrelsen Stockholm (2015), 2015-2-3.
[13] S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, et al., Management
of hyperglycemia in type 2 diabetes, 2015: a patient-centered
approach update to a position statement of the American
Diabetes Association and the European Association for the
Study of Diabetes, Diabetes Care 38 (2015) 140–149.
[14] National Institute for Health and Care Excellence (NICE),
Algorithm for Blood Glucose Lowering Therapy in Adults
with Type 2 Diabetes, NICE guideline NG 28, 2015. Available
from:
https://www.nice.org.uk/guidance/ng28/resources/algorithm-
for-blood-glucose-lowering-therapy-in-adults-with-type-2-di
-2185604173.
[15] D. Russell-Jones, R. Khan, Insulin-associated weight gain in
diabetes—causes, effects and coping strategies, Diabetes
Obes. Metab. 9 (6) (2007) 799–812.
[16] B.T. Srinivasan, J. Jarvis, K. Khunti, M.J. Davies, Recent
advances in the management of type 2 diabetes mellitus: a
review, Postgrad. Med. J. 84 (996) (2008) 524–531.
[17] T.M. Davis, R.M. Clifford, W.A. Davis, Effect of insulin therapy
on  quality of life in Type 2 diabetes mellitus: the Fremantle
Diabetes Study, Diabetes Res. Clin. Pract. 52 (1) (2001) 63–71.
[18] S.E. Holden, S. Jenkins-Jones, C.L. Morgan, et al.,
Glucose-lowering with exogenous insulin monotherapy in
type 2 diabetes: dose association with all-cause mortality,
cardiovascular events and cancer, Diabetes Obes. Metab. 17
(4) (2015) 350–362.
[19] R.M. Stoekenbroek, K.L. Rensing, S.J. Bernelot Moens, et al.,
High daily insulin exposure in patients with type 2 diabetes
is  associated with increased risk of cardiovascular events,
Atherosclerosis 240 (2) (2015) 318–323.
[20] C.L. Roumie, R.A. Greevy, C.G. Grijalva, et al., Association
between intensification of metformin treatment with
insulin vs sulfonylureas and cardiovascular events and
all-cause mortality among patients with diabetes, JAMA 311
(22)  (2014) 2288–2296.
[21] American Diabetes Association, Economic costs of diabetes utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
in  the U.S. in 2007, Diabetes Care 31 (3) (2008) 596–615.
[22] U. Sabale, J. Bodegard, J. Sundstrom, et al., Healthcare
utilization and costs following newly diagnosed type-2
ARTICLE IN PRESSPCD-568; No. of Pages 9
 e s xp  r i m a r y c a r e d i a b e t
diabetes in Sweden: a follow-up of 38,956 patients in a
clinical practice setting, Prim. Care Diabetes 9 (5) (2015)
330–337.
[23] B. Berger, G. Stenstrom, G. Sundkvist, Incidence, prevalence,
and mortality of diabetes in a large population: a report
from the Skaraborg Diabetes Registry, Diabetes Care 22 (5)
(1999) 773–778.
[24] Diabetes National Data US: National Center for Chronic
Disease Prevention and Health Promotion, Division of
Diabetes Translation. National Diabetes Report, 2014.
Available from:
http://www.cdc.gov/diabetes/pubs/statsreport14/national
-diabetes-report-web.pdf.
[25] J.B. Brown, G.A. Nichols, H.S. Glauber, A.W. Bakst, Type 2
diabetes: incremental medical care costs during the first 8
years after diagnosis, Diabetes Care 22 (7) (1999) 1116–1124.
[26] F. Henriksson, C.D. Agardh, C. Berne, et al., Direct medical
costs for patients with type 2 diabetes in Sweden, J. Intern.
Med. 248 (5) (2000) 387–396.
[27] B. Jonsson, C.A. Board, Revealing the cost of type II diabetes
in  Europe, Diabetologia 45 (7) (2002) S5–12.
[28] M. Brandle, H. Zhou, B.R. Smith, et al., The direct medical
cost of type 2 diabetes, Diabetes Care 26 (8) (2003) 2300–2304.
[29] A. Ringborg, M. Martinell, J. Stålhammar, et al., Resource use
and  costs of type 2 diabetes in Sweden—estimates from
population-based register data, Int. J. Clin. Pract. 62 (5) (2008)
708–716.
[30] K. Bolin, C. Gip, A.C. Mörk, B. Lindgren, Diabetes, healthcare
cost and loss of productivity in Sweden 1987 and 2005—a
register-based approach, Diabet. Med. 26 (September (9))
(2009) 928–934.
[31] C. Bexelius, J. Lundberg, X. Wang, et al., Annual medical
costs of Swedish patients with type 2 diabetes before and
after insulin initiation, Diabetes Ther. 4 (December (2)) (2013)
363–374.
[32] I. Grundvold, J. Bodegard, P.M. Nilsson, et al., Body weight
and risk of atrial fibrillation in 7,169 patients with newly
diagnosed type 2 diabetes; an observational study,Please cite this article in press as: A. Kalkan, et al., Increased healthcare
diabetes: A long-term follow-up in clinical practice, Prim. Care Diab. (2016
Cardiovasc. Diabetol. 14 (2015) 5.
[33] H. Glick, J. Doshi, A. Sonnad, D. Polsky, Analyzing Censored
Cost. Economic Evaluatuation in Clinical Trial, Oxford
University Press, 2010, pp. 115–131. x x ( 2 0 1 6 ) xxx–xxx 9
[34] M. Aagren, W.  Luo, Association between glycemic control
and short-term healthcare costs among commercially
insured diabetes patients in the United States, J. Med. Econ.
14  (1) (2011) 108–114.
[35] M. Alvarsson, G. Sundkvist, I. Lager, et al., Effects of insulin
vs  glibenclamide in recently diagnosed patients with type 2
diabetes: a 4-year follow-up, Diabetes Obes. Metab. 10 (5)
(2008) 421–429.
[36] L.B. Harrison, B. Adams-Huet, P. Raskin, I. Lingvay, Beta-cell
function preservation after 3.5 years of intensive diabetes
therapy, Diabetes Care 35 (7) (2012) 1406–1412.
[37] J. Weng, Y. Li, W.  Xu, et al., Effect of intensive insulin therapy
on  beta-cell function and glycaemic control in patients with
newly diagnosed type 2 diabetes: a multicentre randomised
parallel-group trial, Lancet 371 (9626) (2008) 1753–1760.
[38] S. Zoungas, A. Patel, J. Chalmers, et al., Severe hypoglycemia
and risks of vascular events and death, N. Engl. J. Med. 363
(15) (2010) 1410–1418.
[39] K. Eeg-Olofsson, J. Cederholm, P.M. Nilsson, et al., Risk of
cardiovascular disease and mortality in overweight and
obese patients with type 2 diabetes: an observational study
in  13,087 patients, Diabetologia 52 (January (1)) (2009) 65–73.
[40] J. Klenk, K. Rapp, H. Ulmer, et al., Changes of body mass
index in relation to mortality: results of a cohort of 42,099
adults, PLoS One 9 (January (1)) (2014) e84817.
[41] Look AHEAD Research Group, R.R. Wing, Long-term effects
of a lifestyle intervention on weight and cardiovascular risk
factors in individuals with type 2 diabetes mellitus:
four-year results of the Look AHEAD trial, Arch. Intern. Med.
170 (September (17)) (2010) 1566–1575.
[42] J. Mukherjee, C. Sternhufvud, N. Smith, et al., Association
between weight change, clinical outcomes, and health care
costs in patients with type 2 diabetes, J. Manag. Care Spec.
Pharm. 22 (5) (2016) 449–466.
[43] U. Sabale, J. Bodegård, J. Sundström et al. Changes in body
mass index over time and their association with healthcare
costs among newly-diagnosed type-2 diabetes patients in
Sweden, forthcoming. utilization costs following initiation of insulin treatment in type 2
), http://dx.doi.org/10.1016/j.pcd.2016.11.002
[44] The ECOBIM Study, T. Dilla, A. Valladares, C. Nicolay, et al.,
Healthcare costs associated with change in body mass index
in patients with type 2 diabetes mellitus in Spain, Appl.
Health Econ. Health Policy 10 (6) (2012) 417–430.
